

CD47 suppresses phagocytosis by repositioning SIRPA and preventing integrin activation

Meghan A. Morrissey^{1,2} and Ronald D. Vale^{1,2*}.

¹Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158

²Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA 94158

*Corresponding Author

1 **Summary**

2

3 Macrophages must engulf dead cells, debris, and pathogens, while selecting against
4 healthy cells to prevent autoimmunity. Healthy cells express CD47 on their surface,
5 which activates the SIRPA receptor on macrophages to suppress engulfment. Cancer
6 cells overexpress CD47 to evade clearance by the innate immune system, making the
7 CD47-SIRPA signaling axis an appealing therapeutic target. However, the mechanism
8 by which CD47-SIRPA inhibits engulfment remains poorly understood. Here, we dissect
9 SIRPA signaling using a reconstituted target with varying concentrations of activating
10 and inhibitor ligands. We find that SIRPA is excluded from the phagocytic synapse
11 between the macrophage and its target unless CD47 is present. Artificially directing
12 SIRPA to the kinase-rich synapse in the absence of CD47 activates SIRPA and
13 suppresses engulfment, indicating that the localization of the receptor is critical for
14 inhibitory signaling. CD47-SIRPA inhibits integrin activation in the macrophage,
15 reducing macrophage-target contact and suppressing phagocytosis. Chemical
16 activation of integrins can override this effect and drive engulfment of CD47-positive
17 targets, including cancer cells. These results suggest new strategies for overcoming
18 CD47-SIRPA inhibition of phagocytosis with potential applications in cancer
19 immunotherapy.

20 **Introduction**

21
22 The innate immune system is finely balanced to rapidly activate in response to
23 pathogenic stimuli, but remain quiescent in healthy tissue. Macrophages, key effectors
24 of the innate immune system, measure activating and inhibitory signals to set a
25 threshold for engulfment and cytokine secretion. The cell surface protein CD47 is a
26 “Don’t Eat Me” signal that protects healthy cells from macrophage engulfment and is
27 often upregulated by cancer cells to evade innate immune detection (Chao et al., 2012;
28 Jaiswal et al., 2009; Majeti et al., 2009; Oldenborg et al., 2001, 2000). CD47 function-
29 blocking antibodies result in decreased cancer growth or tumor elimination (Advani et
30 al., 2018; Chao et al., 2010a; Gholamin et al., 2017; Jaiswal et al., 2009; Willingham et
31 al., 2012). Despite the therapeutic promise of manipulating CD47 signaling, the
32 mechanism by which CD47 suppresses macrophage signaling is unclear.

33
34 CD47 on the surface of cancer cells binds to SIRPA in macrophages or dendritic cells to
35 prevent activation (Jiang et al., 1999; Liu et al., 2015; Okazawa et al., 2005; Seiffert et
36 al., 1999; Tseng et al., 2013; Yi et al., 2015). Activation of the inhibitory receptor SIRPA
37 must be controlled with high fidelity to suppress engulfment of viable cells when CD47 is
38 present while allowing for robust engulfment of targets lacking CD47. CD47 binding
39 triggers SIRPA phosphorylation by Src family kinases (Barclay and Brown, 2006), but
40 how CD47 binding is translated across the cell membrane to drive SIRPA
41 phosphorylation is not known. Activated SIRPA recruits the phosphatases SHP-1 and
42 SHP-2 (Fujioka et al., 1996; Noguchi et al., 1996; Okazawa et al., 2005; Oldenborg et
43 al., 2001; Veillette et al., 1998). The downstream events that shut off the engulfment
44 program are not clear.

45
46 In vivo, CD47 has been reported to suppress multiple different pro-engulfment “Eat Me”
47 signals, including IgG, complement and calreticulin (Chen et al., 2017; Gardai et al.,
48 2005; Oldenborg et al., 2001). This complexity, in addition to substantial variation in
49 target size, shape and concentration of “Eat Me” signals, can make a quantitative,
50 biochemical understanding of receptor activation difficult. To overcome this problem, we

51 utilize a synthetic target cell-mimic with a defined complement of signals to interrogate
52 the mechanism of SIRPA activation and its downstream targets. We find that CD47
53 ligation alters SIRPA localization, positioning SIRPA for activation at the phagocytic
54 synapse. At the phagocytic synapse, SIRPA inhibits integrin activation to limit
55 macrophage spreading across the surface of the engulfment target. Directly activating
56 integrin eliminated the effect of CD47 and rescued engulfment. Activation of integrin
57 also allowed macrophages to engulf cancer cells, similar to the effect observed with a
58 CD47 function-blocking antibody.

59 **Results**

60

61 **CD47-SIRPA signaling suppresses IgG and phosphatidylserine “Eat Me” signals**

62

63 To study the mechanism of “Eat Me” and “Don’t Eat Me” signal integration during
64 engulfment, we used a reconstituted engulfment target (Figure 1A). Silica beads were
65 coated in a supported lipid bilayer to mimic the surface of a cancer cell. To activate
66 engulfment, we introduced IgG, a well-defined “Eat Me” signal that synergizes with
67 CD47 blockade to promote cancer cell clearance (Chao et al., 2010a; Freeman and
68 Grinstein, 2014). IgG is recognized by the Fc γ Receptor family (FcR), which activates
69 downstream signaling and engulfment (Freeman and Grinstein, 2014). To activate
70 SIRPA, we incorporated the CD47 extracellular domain at a surface density selected to
71 mimic the CD47 density on cancer cells (~ 600 molecules/ μm^2 , Figure S1).

72

73 Using this system, we tested the effect of CD47 on engulfment across a titration of IgG
74 densities (Figure S1). We mixed beads with the macrophage-like cell line RAW264.7
75 and measured the number of internalized beads by confocal microscopy. We found that
76 CD47-SIRPA signaling suppressed engulfment at intermediate IgG densities, but did
77 not appreciably affect engulfment of targets with high densities of bound IgG (Figure 1B-
78 D). This suppression was dependent on CD47 binding as a mutated CD47 extracellular
79 domain (F37D, T115K) that is unable to bind to SIRPA (Hatherley et al., 2008) was also
80 unable to suppress engulfment.

81

82 We further examined whether CD47-SIRPA signaling could suppress engulfment of
83 targets mimicking apoptotic corpses. A critical “Eat Me” signal from apoptotic corpses is
84 phosphatidylserine, which becomes exposed on the outer leaflet of the plasma
85 membrane during cell stress, apoptosis (Fadok et al., 1992; Poon et al., 2014), and on
86 some cancer cells (Birge et al., 2016; Utsugi et al., 1991). We found that engulfment of
87 beads containing 10% phosphatidylserine in the supported lipid bilayer was inhibited by
88 the inclusion of CD47 on the bilayer (Figure 1E, Figure S1). Together, these data show
89 that CD47-SIRPA signaling can block engulfment driven by IgG and phosphatidylserine.

90 Thus, bilayer-coated beads provide a well-defined and tunable platform for studying the
91 integration of “Eat Me” and “Don’t Eat Me” signals during engulfment.

92

93 **CD47 ligation relocates SIRPA to the phagocytic synapse**

94

95 We next sought to determine the mechanism by which CD47 ligation regulates SIRPA
96 activity. We first examined SIRPA localization during phagocytosis of IgG-coated beads.
97 In the absence of CD47, SIRPA was segregated away from the phagocytic cup that
98 enveloped IgG-coated beads (Figure 2A). Similarly, SIRPA was depleted at the center
99 of the immunological synapse between a macrophage and a supported lipid bilayer
100 containing phosphatidylserine (Figure S2). In contrast, in the presence of CD47, SIRPA
101 remained at the phagocytic cup (Figure 2A). These data demonstrate that CD47 recruits
102 SIRPA to the phagocytic synapse.

103

104 We next sought to address the mechanism of SIRPA segregation away from the
105 phagocytic cup in the presence of IgG and absence of CD47. We hypothesized that
106 exclusion of unligated SIRPA from the synapse could be driven by its heavily
107 glycosylated extracellular domain, either by interactions with the surrounding glycocalyx
108 or steric exclusion from the spatially restricted phagocytic synapse. We therefore
109 created a SIRPA chimeric receptor where the extracellular domain was replaced with a
110 small, inert protein domain (FRB^{ext}-SIRPA; Figure 2B). Unlike full length SIRPA, FRB^{ext}-
111 SIRPA was not segregated away from the cell-target synapse (Figure 2C, D). This
112 result demonstrates that the extracellular domain of SIRPA is required for SIRPA
113 exclusion from the phagocytic cup.

114

115 **Targeting SIRPA to the phagocytic synapse suppresses engulfment**

116

117 Receptor activation by Src family kinases at the phagocytic cup is favored due to
118 exclusion of bulky phosphatases like CD45 (Freeman et al., 2016; Goodridge et al.,
119 2011). We therefore hypothesized that positioning SIRPA at the phagocytic cup may
120 drive receptor activation. To distinguish between the effects of CD47 binding and

121 synapse localization, we developed a chimeric SIRPA receptor that localized to the
122 phagocytic synapse in the absence of CD47. We replaced the SIRPA extracellular
123 domain with the IgG-binding extracellular domain of the Fc γ RI α chain (Figure 2B;
124 termed FcR1^{ext}-SIRPA^{int}). This receptor is driven into the synapse by IgG binding
125 instead of CD47 (Figure 2C, D). Expression of this synapse-localized chimera
126 suppressed engulfment of IgG-coated beads in the absence of CD47 (Figure 2E, Figure
127 S2). Thus, targeting SIRPA to the phagocytic cup is sufficient to inhibit engulfment, even
128 in the absence of its natural ligand CD47.

129
130 As an alternative strategy to control the localization of SIRPA activity, we used a
131 chemically inducible dimerization system (Spencer et al., 1993). We fused one half of
132 the chemically inducible dimer to FcR (FcR γ chain-FKBP) and the second to a soluble
133 SIRPA intracellular domain (FRB-SIRPA^{int}, Figure 2F). In the presence of the small
134 molecule rapamycin, FKBP and FRB form a high-affinity dimer (Spencer et al., 1993),
135 thereby recruiting the SIRPA intracellular domain to FcR. In the absence of rapamycin,
136 cells efficiently engulfed IgG-coated beads (Figure 2F, Figure S2). In contrast,
137 rapamycin-induced recruitment of the SIRPA intracellular domain to the FcR γ chain
138 significantly suppressed engulfment (Figure 2F).

139
140 We next examined the extracellular domain truncation of SIRPA (FRB^{ext}-SIRPA) that
141 was not excluded from the phagocytic synapse (Figure 2B). FRB^{ext}-SIRPA constitutively
142 suppressed engulfment (Figure 2G), demonstrating that exclusion of SIRPA is essential
143 for efficient engulfment. Taken together, these experiments show that CD47 activates
144 SIRPA by recruiting it to the phagocytic synapse.

145 146 **FcR phosphorylation is not a major target of CD47-SIRPA signaling**

147
148 We next sought to determine how activated SIRPA inhibits engulfment. Phosphorylated
149 SIRPA recruits the phosphatases SHP-1 and SHP-2 via their phosphobinding SH2
150 domains but the downstream targets of SHP-1 and SHP-2 are not known (Fujioka et al.,
151 1996; Noguchi et al., 1996; Okazawa et al., 2005; Oldenborg et al., 2001; Veillette et al.,

152 1998). One potential target of SIRPA-bound SHP phosphatases is FcR itself. When
153 encountering an IgG-bound bilayer, macrophages clustered IgG into mobile
154 microclusters (Figure 3, Movie S1) that recruited Syk (Figures S3 (Lin et al., 2016)).
155 When CD47 was present, these microclusters still formed and recruited Syk, suggesting
156 that FcR is still phosphorylated (Figures 3A and S3, Movie S2). Further, when we
157 looked at SIRPA localization at the cell-target interface at high resolution, we found that,
158 even in the presence of CD47, SIRPA did not co-localize with FcR clusters, suggesting
159 that SIRPA is not positioned to dampen receptor activation (Figure S3). Overall, this
160 suggests that changes to FcR activation and Syk recruitment are unlikely to account for
161 the effect of SIRPA, consistent with previous biochemical observations (Okazawa et al.,
162 2005; Tsai and Discher, 2008).

163

164 **CD47 prevents integrin activation**

165

166 During our TIRF experiments, we observed a difference in the spreading of cells on
167 bilayers containing IgG alone versus IgG plus CD47. On IgG-coated bilayers, cells
168 rapidly spread across the bilayer surface (Figure 3A, Movie S1). In contrast,
169 macrophages encountering an IgG and CD47-containing bilayer exhibited reduced cell
170 spreading (Figure 3A and 3B, Movie S2). These data shows that CD47 inhibits cell
171 spreading across a target substrate.

172

173 Cell spreading is thought to involve activation of integrins and the actin cytoskeleton
174 (Springer and Dustin, 2011). Inactive integrins exist in a low affinity, bent confirmation
175 (Springer and Dustin, 2011). Upon activation, the extracellular domain extends into an
176 open conformation that can bind many ligands with high affinity (Freeman and Grinstein,
177 2014; Springer and Dustin, 2011). FcR activation stimulates inside-out activation of
178 integrins (Dupuy and Caron, 2008; Jones et al., 1998). Activated integrins can then
179 promote engulfment, either by increasing adhesion to the target particle or by
180 reorganizing the actin cytoskeleton (Dupuy and Caron, 2008; Wong et al., 2016). We
181 found that inhibiting integrin with a $\beta 2$ integrin function-blocking antibody (2E6) or Fab

182 dramatically decreased engulfment efficiency (Figure 3C and S3), demonstrating that
183 inactivating integrins is sufficient to suppress engulfment.

184

185 Because integrin is required for cell spreading and engulfment (Springer and Dustin,
186 2011), we hypothesized that CD47-SIRPA signaling may inhibit engulfment by
187 preventing inside-out activation of integrin. Supporting this hypothesis, a previous study
188 identified phosphopaxillin, which is specifically recruited to sites of integrin activation, as
189 one of a number of phosphoproteins affected by CD47 (Geiger et al., 2009; Tsai and
190 Discher, 2008). We found that the enrichment of phospho-paxillin at the interface of the
191 macrophage with an IgG-coated bead was substantially diminished by the simultaneous
192 presence of CD47 on the bead (Figure 3D). Together, these data indicate that CD47-
193 SIRPA signaling prevents integrin activation.

194

195 **Activating integrin bypasses CD47-SIRPA inhibitory signaling**

196

197 CD47-SIRPA has previously been reported to affect paxillin and myosin
198 phosphorylation, as well as F-actin recruitment (Tsai and Discher, 2008). It is not clear
199 which of these is a target of CD47 signaling and which is a secondary effect of altered
200 upstream signaling (Tsai and Discher, 2008). We hypothesized that if SIRPA signaling
201 suppresses engulfment primarily by inhibiting integrin inside-out activation, then directly
202 activating integrin might bypass SIRPA-mediated inhibition and permit bead engulfment
203 (Figure 4A). Alternatively, if the target of CD47-SIRPA signaling is in a parallel pathway
204 or downstream of integrin activation, then activating integrin should not rescue
205 engulfment following SIRPA activation. To activate integrin, we treated macrophages
206 with manganese, which locks integrin into a high-affinity open conformation (Dransfield
207 et al., 1992). We found that macrophages treated with 1 mM manganese engulfed
208 beads with a similar efficiency whether or not CD47 was conjugated to the supported
209 lipid bilayer (Figure 4B). Importantly, manganese did not trigger bead engulfment on its
210 own or dramatically enhance engulfment of IgG-coated beads in the absence of CD47
211 (Figure 4B,C), establishing that increasing integrin activation is not sufficient to trigger

212 engulfment. Thus, a manganese-induced increase in engulfment was specific to beads
213 coated with CD47 and IgG.

214

215 As an alternative strategy to activate integrins, we incubated macrophages with beads
216 containing a surplus of high affinity integrin ligand, ICAM-1 (Springer and Dustin, 2011).
217 ICAM-1 was sufficient to activate integrin and recruit phosphatidylinositol even in the
218 presence of CD47 (Figure 4D). Inclusion of high concentrations of ICAM-1 abrogated
219 the inhibitory effect of CD47 on phagocytosis, but did not dramatically alter the
220 engulfment efficiency of IgG coated beads in the absence of CD47 (Figure 4E).

221

222 CD47 has previously been reported to inhibit downstream steps in the phagocytic
223 signaling pathway, including actin accumulation at the phagocytic cup (Tsai and
224 Discher, 2008). Despite the presence of CD47, ICAM-1-bound beads had similar levels
225 of actin accumulation as beads lacking CD47 (Figure 4F). This demonstrates that
226 activating integrins reactivates downstream signaling in the presence of CD47.
227 Together, these data suggest that inside-out activation of integrin is the primary target of
228 CD47-SIRPA signaling.

229

230 **Integrin activation drives cancer cell engulfment**

231

232 Many cancer cells overexpress CD47 to evade the innate immune system despite
233 increased expression of “Eat Me” signals such as calreticulin or phosphatidylserine
234 (Birge et al., 2016; Chao et al., 2010b; Gardai et al., 2005; Utsugi et al., 1991). Blocking
235 CD47 with a therapeutic antibody allows “Eat Me” signals to dominate, resulting in
236 engulfment of whole cancer cells (Jaiswal et al., 2009; Majeti et al., 2009). We
237 hypothesized that exogenous activation of integrin would bypass the CD47 signal on the
238 surface of cancer cells, allowing for engulfment. To test this, we incubated bone marrow
239 derived mouse macrophages with a CD47-positive murine leukemia line, L1210 (Chen
240 et al., 2017). We found that activating integrins with 100 μ M manganese increased the
241 ability of macrophages to engulf cancer cells, reaching a similar efficiency as treatment
242 with a CD47 function-blocking antibody (Figure 4G,H; Movie S3). Manganese did not

243 directly affect cancer cell viability over the time course of this experiment (Figure S4).
244 This data shows that activating integrins bypasses the suppressive CD47 signal on the
245 surface of cancer cells.

246 **Discussion**

247

248 CD47-SIRPA signaling suppresses engulfment, protecting viable cells and allowing
249 cancer cells to evade the innate immune system (Jaiswal et al., 2009; Majeti et al.,
250 2009; Oldenborg et al., 2000). Although CD47 blockade is a promising new target for
251 cancer therapies (Advani et al., 2018; Gholamin et al., 2017; Willingham et al., 2012),
252 the mechanism of CD47-SIRPA signaling has not been clarified. We demonstrate that
253 localizing SIRPA to the phagocytic synapse is sufficient to activate this inhibitory
254 receptor. Once active, SIRPA suppresses engulfment by preventing integrin activation
255 (Figure 4I).

256

257 Our results demonstrate that SIRPA localization is a key determinant of its activity. In
258 the absence of CD47, SIRPA is relegated to the phosphatase-rich zone outside the cell
259 bead interface (Freeman et al., 2016; Goodridge et al., 2011). This localization prevents
260 SIRPA activation. Conversely, CD47 binding retains SIRPA at the Src-kinase rich
261 phagocytic cup, where it is activated and suppresses engulfment. Spatial segregation of
262 Src-family kinase activity at the central phagocytic synapse and CD45 phosphatase
263 activity at the periphery underlies the activation of many activating receptors (TCR, Fc
264 Receptor, (Freeman et al., 2016; James and Vale, 2012). Our work expands this model,
265 suggesting that exclusion of inhibitory receptors like SIRPA may be a pre-requisite for
266 efficient engulfment. Further, these data suggest a new paradigm for regulating
267 inhibitory receptors based on conditional recruitment to the immunological synapse.

268

269 SIRPA exclusion from the phagocytic synapse in the absence of CD47 prevents basal
270 inhibition of engulfment and allows positive signaling to dominate. This exclusion
271 requires the extracellular domain of SIRPA, as replacing the extracellular domain with a
272 small, inert protein (FRB) allowed SIRPA to enter the phagocytic synapse (Figure 2).
273 CD45, the transmembrane phosphatase that negatively regulates Fc Receptor
274 activation, is sterically excluded from the synapse between a T cell or macrophage and
275 its target (Freeman et al., 2016; Goodridge et al., 2011; James and Vale, 2012). The
276 SIRPA extracellular domain is predicted to be smaller than CD45 (aglycosylated

277 proteins are 12 nm and 17 nm respectively (Chang et al., 2016; Hatherley et al., 2008).
278 Biophysical studies have shown that proteins that are the same size or slightly smaller
279 than the height of a cell-cell synapse are excluded from the synapse due to steric
280 constraints (Schmid et al., 2016). Ligand binding is sufficient to drive synapse
281 localization (Schmid et al., 2016). Thus SIRPA may be sterically excluded unless CD47
282 ligation overcomes the energetic barrier preventing SIRPA from entering the
283 immunological synapse. Alternatively, other mechanisms, such as lateral crowding or
284 interactions with the surrounding glycocalyx, could drive SIRPA exclusion from the
285 synapse.

286
287 After addressing the mechanism of SIRPA activation, we sought to identify the targets
288 of CD47-SIRPA signaling. Previous work has shown that SIRPA activation dramatically
289 reduces global phosphotyrosine, including phosphorylation of mDia, paxillin, talin,
290 alpha-actinin and non-muscle myosin IIA (Okazawa et al., 2005; Tsai and Discher,
291 2008). However, discerning between direct targets of SIRPA-bound phosphatases and
292 indirect targets resulting from an upstream block in the engulfment signaling cascade
293 has been challenging. Because blocking non-muscle myosin II decreases phagocytosis
294 to a similar extent as CD47, myosin has been presumed to be the primary target of
295 SIRPA (Chao et al., 2012; Tsai and Discher, 2008). However, we demonstrate that the
296 inhibitory effect of CD47-SIRPA can be eliminated by re-activating integrin, suggesting
297 that the direct targets of SIRPA-bound SHP phosphatases are upstream of integrin
298 activation. SHP-2 has previously been shown to directly dephosphorylate Fak (Yu et al.,
299 1998) and vinculin (Campbell et al., 2018), thus SHP-2 may act upon these key integrin
300 regulators. However, given the broad specificity of SHP-1 and SHP-2, these
301 phosphatases may dephosphorylate several targets at the phagocytic cup to suppress
302 signaling.

303
304 Our work provides new insights into the connection between SIRPA and integrins. While
305 phosphopaxillin (Tsai and Discher, 2008), has previously been shown to be affected by
306 CD47-SIRPA, the relative importance of integrin signaling had not previously been
307 addressed. We show that CD47-SIRPA prevents integrin activation, allowing

308 macrophages to quickly discriminate between targets based on the presence of CD47.
309 SIRPA overexpression has previously been shown to decrease surface levels of integrin
310 over time (Liu et al., 2008). While this decrease in integrin expression does not explain
311 how SIRPA immediately prevents phagocytosis of a CD47-bound target, it suggests that
312 long term exposure to activated SIRPA may decrease overall phagocytic capacity, even
313 of targets lacking CD47. In addition, SIRPA has been implicated in regulating cell
314 motility, as fibroblasts lacking SIRPA have impaired motility (Alenghat et al., 2012;
315 Inagaki et al., 2000; Motegi et al., 2003). In this case, un-ligated SIRPA may instead act
316 downstream of integrin, as eliminating SIRPA decreases integrin responsiveness
317 (Alenghat et al., 2012; Inagaki et al., 2000).

318
319 By suppressing integrin activation, CD47-SIRPA signaling may be able to suppress
320 many different signaling pathways. Interestingly, CD47 has been reported to affect
321 dendritic cell activation, cancer cell killing via a nibbling behavior (called trogocytosis),
322 and complement-mediated engulfment (Caron et al., 2000; Matlung et al., 2018;
323 Oldenborg et al., 2001; Tamada et al., 2004; Wu et al., 2018; Yi et al., 2015). These
324 processes are triggered by diverse positive signaling receptors, but all require inside-out
325 activation of integrin (Caron et al., 2000; Matlung et al., 2018; Oldenborg et al., 2001;
326 Tamada et al., 2004; Wu et al., 2018; Yi et al., 2015). Targeting integrin, a common co-
327 receptor, may explain how CD47-SIRPA signaling can regulate these diverse
328 processes.

329
330 Finally, we found that integrin activation by manganese can drive engulfment of whole
331 cancer cells by bone marrow derived macrophages. As a cancer treatment, CD47
332 blockade synergizes with therapeutic antibodies, like rituximab (Advani et al., 2018;
333 Chao et al., 2010a). Activating integrins with a small molecule agonist in combination
334 with antibody therapeutics may have a similar synergistic effect as CD47 blockade.
335 Small molecule agonists of CD11b, an integrin subunit highly expressed in
336 macrophages, drive tumor regression in a macrophage-dependent manner (Panni et al.,
337 2019; Schmid et al., 2018). Our data suggests that these small molecules may allow
338 macrophages to bypass the CD47 inhibitory signal.

339 **Acknowledgments**

340

341 We thank K. McKinley and O. Klein for providing mouse long bones as a source for
342 hematopoietic stem cells. We thank members of the Vale lab for critical feedback on this
343 manuscript. M.A.M. was supported by the National Institute of General Medical
344 Sciences of the National Institutes of Health under award number F32GM120990. This
345 work was funded by the Howard Hughes Medical Institute.

346

347 **Competing Financial Interests**

348 The authors declare no competing financial interests.

349

350 **Figure Legends**

351

352 **Figure 1: CD47-SIRPA suppresses IgG and PS dependent engulfment**

353 (A) Schematic shows the supported lipid bilayer system used in this study. Anti-biotin
354 IgG is bound to biotinylated lipids. IgG is recognized by Fc Receptor in the
355 macrophage. The extracellular domain of CD47-His₁₀ is bound to Ni-NTA-conjugated
356 lipids and recognized by SIRPA in the macrophage. (B) Silica beads are coated in a
357 supported lipid bilayer and incubated with the indicated concentration of IgG and
358 either CD47 (red) or an inactive mutant CD47 (F37D, T115K; green). The
359 functionalized beads were added to RAW264.7 macrophages and fixed after 30 min.
360 The average number of beads per macrophage was assessed by confocal microscopy
361 and normalized to the maximum bead eating observed in that replicate. Each dot
362 represents an independent replicate (n≥100 cells analyzed per experiment), and the
363 trendline connects the average of three replicates. (C) Still images depict the assay
364 described in (B). The supported lipid bilayers contain the fluorescently-labeled lipid
365 atto390-DOPE (green) and the macrophages membranes are labeled with CellMask
366 (magenta). Internalized beads are indicated with a yellow dot. (D) Histograms depict
367 the fraction of cells engulfing the indicated number of beads (pooled data from the
368 three independent replicates shown in (B)). Macrophages encountering CD47-
369 conjugated beads (right) were less likely to engulf, and those that did engulfed fewer
370 beads. CD47^{F37D,T115K}, a mutant that cannot bind SIRPA, was used as a control. (E)
371 Macrophages were incubated with beads coated in a supported lipid bilayer containing
372 10% phosphatidylserine and either CD47 or the inactive CD47^{F37D,T115K}. Data was
373 normalized to the maximum bead eating observed in that replicate. The complete,
374 pooled data is shown in Supplementary Figure 1E. Dots and error bars denote the
375 mean and standard error of independent replicates. *** indicates p<0.0005 by a
376 Kruskal-Wallis test on the pooled data (B and E). Scale bar denotes 5 μm in this and
377 all subsequent figures.

378

379 **Figure 2: Forcing SIRPA into the macrophage-target synapse suppresses**
380 **engulfment**

381 (A) SIRPA-GFP (top; green in merge) is depleted from the base of the phagocytic cup
382 (arrow) when a macrophage engulfs a bead functionalized with IgG and CD47^{F37D},
383 ^{T115K}, which cannot bind SIRPA (left; supported lipid bilayer, magenta). SIRPA is not
384 depleted when CD47 is present (IgG+CD47, right). Graph depicts the ratio of SIRPA-
385 GFP at the phagocytic cup/cell cortex for individual phagocytic cups. (B) A schematic
386 shows the chimeric SIRPA constructs in this figure. Full length SIRPA is on the right,
387 FRB^{ext}-SIRPA is in the center and FcRI^{ext}-SIRPA^{int}-GFP is on the left. (C) SIRPA-GFP,
388 FRB^{ext}-SIRPA-GFP and FcRI^{ext}-SIRPA^{int}-GFP fluorescence is shown at cell-bead
389 contacts (arrow). (D) Graph depicts the ratio of GFP fluorescence at the synapse
390 (arrow in C) compared to the cortex for the indicated SIRPA chimeras. (E) A graph
391 depicts the average number of internalized IgG beads per macrophage expressing the
392 chimeric SIRPA constructs schematized in (B), normalized to macrophages
393 expressing only a membrane-tethered GFP (GFP-CAAX). (F) Schematic (left) shows a
394 system for inducible recruitment of the SIRPA intracellular domain to the phagocytic
395 cup. Recruiting SIRPA to the phagocytic cup suppresses engulfment compared to
396 soluble SIRPA or compared to wild-type macrophages treated with rapamycin
397 (normalized to uninfected macrophages). (G) The graph shows the number of beads
398 engulfed by uninfected, SIRPA-GFP or FRB^{ext}-SIRPA expressing macrophages
399 normalized to uninfected cells. In A and D, dots represent individual cups, red lines
400 show mean \pm SD and data is pooled from three independent experiments. In E, F and
401 G, dots show the average from an independent replicate with the error bars denoting
402 SEM for that replicate. The complete pooled data showing the number of beads eaten
403 per macrophage is shown in Figure S2. *** denotes $p < 0.0005$, ** denotes $p < 0.005$ and
404 * denotes $p < 0.05$ as determined by a Student's T test (A, D) or a Kruskal-Wallis test
405 on the pooled data from all three replicates (E, F, G).

406

407 **Figure 3: CD47 prevents integrin activation**

408 (A) Still images from a TIRF microscopy timelapse show that macrophages form IgG
409 (black) microclusters as they spread across an IgG bilayer (top). Adding CD47 to the
410 bilayer inhibits cell spreading (bottom; graphed on right, average area of contact from
411 $n \geq 11$ cells \pm SEM, pooled from three separate experiments). (B) TIRF images show

412 the cell membrane (mCherry-CAAX; white) of macrophages engaging with an IgG
413 (left) or IgG and CD47 (right) bilayer. Graphs depict the average number of cells seen
414 contacting the bilayer after 10 min (center) and the average area of cell contact (right).
415 Each dot represents an individual field of view (center) or cell (right) pooled from three
416 independent experiments. (C) Diagram shows that IgG binding activates Fc Receptor,
417 which triggers downstream signaling events including inside-out activation of integrins.
418 Blocking integrin activation using a function-blocking antibody (2E6) targeting the $\beta 2$
419 integrin subunit decreased the efficiency of engulfment (graphed in center panel,
420 normalized to the isotype control, with error bars denoting SEM of each replicate). (D)
421 Immunofluorescence images show phosphopaxillin (top; green in merge) and F-actin
422 (center; magenta in merge; visualized with phalloidin) at the phagocytic cup of an IgG
423 coated bead (left) or an IgG- and CD47-coated bead (right). Graphs show the ratio of
424 phosphopaxillin intensity at the phagocytic cup/cell cortex. Each dot represents an
425 individual phagocytic cup; lines denote the mean \pm SD. The non-activating CD47^{F37D},
426 T^{115K} was used as a control on bilayers lacking CD47. *** denotes $p < 0.0005$, **
427 denotes $p < 0.005$, and * denotes $p < 0.05$ as determined by Student's T test (A, B and
428 D) or a Kruskal-Wallis test on the pooled data (C).

429

430 **Figure 4: Bypassing inside out activation of integrin eliminates the effect of**
431 **CD47.**

432 (A) The schematic shows a simplified signaling diagram. If CD47 and SIRPA act
433 upstream of integrin, then providing an alternate means of integrin activation (Mn^{2+} or
434 ICAM) should eliminate the effect of CD47. (B) Macrophages were treated with 1 mM
435 Mn^{2+} and fed beads with IgG and either CD47 (red) or the non-signaling CD47^{F37D},
436 T^{115K} (green). Bars denote the average number of beads eaten from the pooled data of
437 three independent replicates \pm SEM. (C) Beads were incubated with the indicated
438 concentration of IgG and added to macrophages. Treatment with Mn^{2+} did not
439 dramatically enhance engulfment (black, compared to grey). Dots represent the
440 average number of beads eaten \pm SEM in one data set representative of three
441 experiments. (D) Immunofluorescence shows that adding ICAM (10 nM coupling
442 concentration) to IgG + CD47 beads rescues phosphopaxillin (top; green in merge,

443 bottom) at the phagocytic cup. Compare to data displayed in Figure 3D ($p < 0.0005$ for
444 phosphopaxilin with ICAM and CD47 compared to CD47 alone). (E) Beads were
445 functionalized with IgG and either CD47 (red) or the non-signaling CD47^{F37D, T115K}
446 (green). Adding ICAM to the beads abrogated the effect of CD47 (center) but did not
447 stimulate engulfment without IgG (right). (F) ICAM also rescued actin accumulation at
448 the phagocytic cup as measured by the ratio of phalloidin fluorescence at the cup to
449 the cell cortex. (G) Bone marrow-derived macrophages expressing a membrane
450 tethered GFP (GFP-CAAX) were incubated with L1210 murine leukemia cells
451 expressing H2B-mCherry. Treating with 100 μ M manganese allowed for engulfment of
452 whole cancer cells. These images correspond to frames from Movie S3. (H) The
453 percent of macrophages engulfing a cancer cell during an 8 hr timelapse is graphed.
454 Each dot represents an independent replicate, with lines denoting mean \pm SEM. (I)
455 Model figure shows that in the absence of CD47 (left), SIRPA is segregated away
456 from the phagocytic synapse and Fc Receptor binding triggers inside out activation of
457 integrin. When CD47 is present (right), SIRPA localizes to the synapse and inhibits
458 integrin activation. *** denotes $p < 0.0005$, ** denotes $p < 0.005$ and n.s. denotes $p > 0.05$
459 as determined by a Kruskal-Wallis test (B, E), Ordinary One-way ANOVA (D, F) or
460 Fisher Exact (H) on the pooled data from all three replicates.
461

462 **Materials and Methods**

463

464 **Cell culture**

465 RAW264.7 macrophages were provided by the ATCC and certified mycoplasma-free.
466 The cells were cultured in DMEM (Gibco, Catalog #11965–092) supplemented with 1 x
467 Pen-Strep-Glutamine (Corning, Catalog #30–009 CI) 1 mM sodium pyruvate (Gibco,
468 Catalog #11360-070) and 10% heat inactivated fetal bovine serum (Atlanta Biologicals,
469 Catalog #S11150H). To keep variation to a minimum, cells were discarded after 20
470 passages. L1210 cells were also acquired from the ATCC.

471 J774A.1 macrophages were provided by the UCSF cell culture facility. J774A.1 and
472 293T cells were tested for mycoplasma using the Lonza MycoAlert Detection Kit (Lonza,
473 Catalog# LT07-318) and control set (Lonza, Catalog #LT07-518).

474 Bone marrow derived macrophages were generated from the hips and long bones of
475 C57BL/6J mice as previously described (Weischenfeldt and Porse, 2008) except that
476 purified 25 ng/ml M-CSF (Peprotech, Catalog # 315–02) was used.

477

478 **Constructs and antibodies**

479 All relevant information is provided in the STAR methods table, including a detailed
480 description of the amino acid sequence of each construct and the catalog number of all
481 antibodies.

482

483 **Lentivirus production and infection**

484 All constructs were expressed in RAW264.7 using lentiviral infection. Lentivirus was
485 produced in HEK293T cells transfected with pMD2.G (a gift from Didier Trono,
486 Addgene plasmid # 12259 containing the VSV-G envelope protein), pCMV-dR8.91
487 (since replaced by second generation compatible pCMV-dR8.2, Addgene plasmid
488 #8455), and a lentiviral backbone vector containing the construct of interest (derived
489 from pHRSIN-CSGW, see STAR methods) using lipofectamine LTX (Invitrogen, Catalog
490 # 15338–100). Constructs are described in detail in the Key Resources Table. The
491 media was harvested 72 hours post-infection, filtered through a 0.45 µm filter and
492 concentrated using LentiX (Takara Biosciences). After addition of the concentrated

493 virus, cells were centrifuged at 2000xg for 45 min at 37°C. Cells were analyzed a
494 minimum of 60 hr later.

495

496 **Supported lipid bilayer assembly**

497 *SUV preparation*

498 The following chloroform-suspended lipids were mixed and desiccated overnight to
499 remove chloroform: 96.8% POPC (Avanti, Catalog # 850457), 2% Ni²⁺-DGS-NTA
500 (Avanti, Catalog # 790404), 1% biotinyl cap PE (Avanti, Catalog # 870273), 0.1%
501 PEG5000-PE (Avanti, Catalog # 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH,
502 Catalog # AD 390–161). The lipid sheets were resuspended in PBS, pH7.2 (Gibco,
503 Catalog # 20012050) and stored under argon. The lipids were broken into small
504 unilamellar vesicles via several rounds of freeze-thaws. The mixture was cleared using
505 ultracentrifugation (TLA120.1 rotor, 35,000 rpm / 53,227 x g, 35 min, 4°C). The lipids
506 were then stored at 4°C under argon for up to two weeks.

507

508 *Planar bilayer preparation for TIRF microscopy*

509 Ibbidi coverslips (catalog #10812) were RCA cleaned. Supported lipid bilayers were
510 assembled in custom plasma cleaned PDMS (Dow Corning, catalog # 3097366-0516
511 and 3097358-1004) chambers at room temperature for 1 hour. Bilayers were blocked
512 with 0.2% casein (Sigma, catalog # C5890) in PBS. Proteins were coupled to the bilayer
513 for 45 min. Imaging was conducted in HEPES buffered saline (20 mM HEPES, 135 mM
514 NaCl, 4 mM KCl, 10 mM glucose, 1 mM CaCl₂, 0.5 mM MgCl₂). Bilayers were assessed
515 for mobility by either photobleaching or monitoring the mobility of single particles.

516

517 *Bead preparation*

518 8.6*10⁸ silica beads with a 5.02 μm diameter (10 μl of 10% solids, Bangs Labs,
519 Catalog # SS05N) were washed three times with PBS, mixed with 1mM SUVs in PBS
520 and incubated at room temperature for 0.5-2 hr with end-over-end mixing to allow for
521 bilayer formation. Beads were then washed three times with PBS to remove excess
522 SUVs and incubated in 100 μl of 0.2% casein (Sigma, catalog # C5890) in PBS for 15
523 min before protein coupling. Unless otherwise indicated, anti-biotin AlexaFluor647-IgG

524 (Jackson ImmunoResearch Laboratories Catalog # 200-602-211, Lot # 137445) was
525 added between 3 and 30 nM, always using the lowest IgG concentration that triggered
526 engulfment. Purified CD47^{ext}-His₁₀ was added at 1 nM. Proteins were coupled to the
527 bilayer for 1 hr at room temperature with end-over-end mixing.

528

529 *Protein density estimation*

530 Given the high affinity of His₁₀ for Ni²⁺-DGS-NTA (0.6 nM (Hui and Vale, 2014)), and
531 antibody-antigen interactions, we expect close to 100% coupling efficiency (Hui and
532 Vale, 2014). Complete coupling would result in 600 molecules/ μm^2 CD47 and 300
533 molecules/ μm^2 IgG for the 3 nM coupling condition. This is well within the range of
534 CD47 on the surface of a cancer cell (Figure S1). In addition, to estimate the amount of
535 IgG bound to each bead, we compared the fluorescence of IgG on the bead surface to
536 calibrated fluorescent beads (Quantum AlexaFluor 647, Bangs Lab) using confocal
537 microscopy. Using this method, we measured 200-360 molecules/ μm^2 of IgG, which is
538 consistent with the theoretical prediction of near complete coupling.

539

540 **Protein Purification**

541 His₁₀-CD47^{ext}, His₁₀-CD47^{ext F37D, T115K} (aa40-182; Uniprot Q61735) and ICAM-tagBFP-
542 His₁₀ (O'Donoghue et al., 2013) were expressed in SF9 or HiFive cells using the Bac-to-
543 Bac baculovirus system as described previously (Hui and Vale, 2014). Briefly, the N-
544 terminal extracellular domain of CD47 was cloned into a modified pFastBac HT A with
545 an upstream signal peptide from chicken RPTP σ (Chang et al., 2016). Insect cell media
546 containing secreted proteins was harvested 72 hr after infection with baculovirus. His₁₀
547 proteins were purified by using Ni-NTA agarose (Qiagen, Catalog # 30230), followed by
548 size exclusion chromatography using a Superdex 200 10/300 GL column (GE
549 Healthcare, Catalog # 17517501). The purification buffer was 30 mM Hepes pH 7.4, 150
550 mM NaCl, 2 mM MgCl₂, 5% glycerol (CD47) or 150 mM NaCl, 50 mM Hepes pH 7.4, 5%
551 glycerol, 2 mM TCEP (ICAM).

552

553 **Phosphopaxilin staining**

554 Macrophages were fixed in 4% PFA for 15 min, then permeabilized and blocked with
555 0.1% BSA in PBS with 0.5% Tween 20. The cells were incubated with the
556 phosphopaxillin antibody at 1:50 dilution at 4° C overnight before incubating with Alexa
557 Fluor 555 anti-rabbit secondary (21428), Alexa Fluor 488 phalloidin (A12379).

558

559 **β2 integrin block and Fab generation**

560 To disrupt integrin function, the 2E6 anti-β2 integrin antibody (ThermoFisher, MA1805)
561 or isotype control (ThermoFisher, 16-4888-81) was added to macrophages at 10 μg/ml
562 30 minutes before IgG-opsonized beads. To eliminate any effects of the Fc domain, we
563 generated Fabs from these antibodies using the Pierce Fab separation kit
564 (ThermoFisher 44985).

565

566 **Whole cell internalization assay**

567 30,000 macrophages infected with GFP-CAAX were plated in a 96-well glass bottom
568 MatriPlate (Brooks, Catalog # MGB096-1-2-LG-L). 2 hours prior to imaging, cells were
569 washed into serum-free, phenol free DMEM for imaging. Manganese (SigmaAldrich,
570 M8054) was added at 100 μM 30 min prior to imaging. or CD47 function-blocking
571 antibody clone miap301 (Biolegend, 127520) was used at 10 mg/ml. 100,000 H2B-
572 mCherry expressing L1210 cells were added and the co-culture was imaged for 8 hr.

573

574 **Microscopy and analysis**

575 Images were acquired on a spinning disc confocal microscope (Nikon Ti-Eclipse
576 inverted microscope with a Yokogawa spinning disk unit and an Andor iXon EM-CCD
577 camera) equipped with a 40 × 0.95 NA air and a 100 × 1.49 NA oil immersion objective.
578 The microscope was controlled using μManager. For TIRF imaging, images were
579 acquired on the same microscope with a motorized TIRF arm, but using a Hamamatsu
580 Flash 4.0 camera and the 100x 1.49 NA oil immersion objective.

581

582 **Quantification of engulfment**

583 30,000 macrophages in one well of a 96-well glass bottom MatriPlate (Brooks, Catalog
584 # MGB096-1-2-LG-L) between 12 and 24 hr prior to the experiment. Macrophages

585 remained in culture media (DMEM with 10% heat inactivated serum) throughout the
586 experiment. Unless otherwise indicated, $\sim 1 \times 10^7$ beads were added to well and
587 engulfment was allowed to proceed for 30 min. Cells were fixed with 4% PFA and
588 stained with CellMask (ThermoFisher, catalog # C10045) without membrane
589 permeabilization to label cell boundaries. Images were acquired using the High Content
590 Screening (HCS) Site Generator plugin in μ Manager (Edelstein et al., 2010).

591

592 **Quantification of synapse intensity of phosphoPaxillin, actin and SIRPA** 593 **constructs**

594 Phagocytic cups were selected for analysis based on the presence of clustered IgG at
595 the cup base (SIRPA chimeras) or clear initiation of membrane extensions around the
596 phagocytic target (actin, phosphopaxillin). The phagocytic cup and the cell cortex were
597 traced with a line 3 pixels wide at the Z-slice with the clearest cross section of the cup.
598 The average background intensity was measured in an adjacent region and subtracted
599 from each measurement.

600

601 **Quantification of the cell-bilayer contact area**

602 For 3A, time-lapse images of macrophages interacting with an IgG or IgG+CD47
603 bilayer were acquired using TIRF microscopy as described above. Macrophages were
604 removed from their culture dish using 5% EDTA in PBS, two times washed and
605 resuspended in the HEPES imaging buffer (20 mM HEPES, 135 mM NaCl, 4 mM KCl,
606 10 mM glucose, 1 mM CaCl_2 , 0.5 mM MgCl_2) before being added to the TIRF chamber.
607 The area of the cell contacting the bilayer was traced in ImageJ beginning with the first
608 frame where the cell can be detected. Only cells with mobile IgG clusters were included.
609 For 3B, the number of macrophage-bilayer contacts and the area was quantified in still
610 images of live cells between 10 and 15 min after cells were added to the bilayer. All
611 cells were included.

612

613 **Statistics**

614 Statistical analysis was performed in Prism 8 (GraphPad, Inc). The statistical test used
615 is indicated in the relevant figure legend.

616 **Supplemental Figure Legends**

617

618 **Figure S1, related to Figure 1: A reconstitution system for studying CD47-SIRPA** 619 **signaling**

620 (A) SDS page gel shows the N-terminal extracellular domain of murine CD47 purified
621 from insect cells using a C-terminal His₁₀. (B) Beads coated in supported lipid bilayers
622 were incubated with the indicated concentration of anti-biotin IgG. The fluorescent
623 intensity of Alexa Fluor 647-IgG on the bead was measured to ensure that the binding
624 of IgG increased with higher coupling concentrations. (C) The estimated surface density
625 of CD47 on red blood cells (Gardner et al., 1991; Mouro-Chanteloup et al., 2003), T
626 cells (Subramanian et al., 2006), cancer cells (Dheilly et al., 2017; Jaiswal et al., 2009;
627 Michaels et al., 2017) and the beads used in this study. (D) IgG surface density was
628 held constant while CD47 density was titrated. The 1 nM CD47 coupling concentration
629 was selected for use throughout this study. (E) Histograms depict the fraction of
630 macrophages engulfing the indicated number of phosphatidylserine beads. The
631 RAW264.7 histograms correspond to the replicates depicted in Figure 1E. RAW264.7
632 engulfment was measured after 30 min and J774A.1 was measured after 90 min.

633

634 **Figure S2, related to Figure 2: Forcing SIRPA into the macrophage-target synapse** 635 **suppresses engulfment**

636 (A) Schematic depicts TIRF imaging. (B) TIRF microscopy of J774A.1 macrophages
637 encountering a 10% phosphatidylserine bilayer reveals that SIRPA-GFP is depleted at
638 the center off the cell-bilayer synapse (top; yellow arrow compared to cyan arrow).
639 Macrophages did not form this zone of depletion when encountering a bilayer containing
640 both phosphatidylserine and CD47 (bottom). The ratio of SIRPA-GFP fluorescent
641 intensity at the cell center/cell edge is quantified on the right. Each dot represents an
642 individual cell and data is pooled from 3 independent experiments. Lines denote the
643 mean \pm SD. *** denotes $p < 0.0005$ by Student's T test. (C) SIRPA-GFP and the chimeric
644 receptors FcRI^{ext}-SIRPA^{int}-GFP and FRB^{ext}-SIRPA are expressed at similar levels.
645 Fluorescent intensity was normalized to the average intensity of SIRPA-GFP in that
646 experiment. Each dot represents an individual cell and data is pooled from 3

647 independent experiments. Lines denote the mean \pm SD. (D, E and F) Histograms depict
648 the fraction of macrophages engulfing the indicated number of IgG-bound beads. The
649 average number of beads per cell is shown \pm SEM. This data corresponds to 1E (D), 1F
650 (E) and 1G (F). For all panels, data is pooled from three data is pooled from 3
651 independent experiments. Lines denote the mean \pm SD.

652

653 **Figure S3, related to Figure 3: CD47 does not affect FcR activation and Syk**
654 **recruitment.**

655 (A) TIRF microscopy shows that macrophages are able to form IgG microclusters (left;
656 cyan in merged image) that recruit Syk (middle; magenta in merged image) if CD47 is
657 absent (top) or present (bottom). Inset shows the boxed region of the image above. The
658 linescan shows the fluorescent intensity of Alexa Fluor 647-IgG and Syk-mCherry at the
659 indicated position (white arrow). Intensity was normalized so that 1 is the highest
660 observed intensity and 0 is background. The fraction of cells able to form IgG clusters
661 and recruit Syk is displayed on the far right. Each dot represents the percent from an
662 independent experiment ($n \geq 20$ per replicate) and the lines denote mean \pm SD. (B)
663 TIRF microscopy shows that, in the presence of CD47, SIRPA (green) does not co-
664 localize with IgG clusters (cyan; arrowheads). Inset shows the boxed region in the
665 above image. The linescan shows the fluorescent intensity of Alexa Fluor 647-IgG and
666 SIRPA-GFP at the position indicated by a white arrow. (C) Macrophages were
667 incubated with a Fab generated from the $\beta 2$ function-blocking antibody (2E6, red) or
668 from an isotype control (green). The pooled data from three independent replicates is
669 graphed with error bars denoting SEM. ** indicates $p < 0.005$ by Kruskal-Wallis test.

670

671 **Figure S4, related to Figure 4: Manganese does not affect L1210 viability**

672 L1210 cells were serum starved for 2 hrs, then treated with 100 μ M manganese for 6
673 hrs as in 2H. The percent of cells that bound high levels of annexin, indicating
674 phosphatidylserine exposure and the initiation of apoptosis, was measured by flow
675 cytometry.

676

677 **Movie S1: Macrophage encounters IgG bound to a supported lipid bilayer.**

678 TIRF imaging (see schematic in Figure S2) shows Alexa Fluor 647-IgG (black) in the
679 supported lipid bilayer as a macrophage engages with an IgG-bound target. Frames
680 were acquired every 20 sec and time is indicated in the top left. Scale bar denotes 5
681 μm .

682

683 **Movie S2: Macrophage encounters IgG and CD47 bound to a supported lipid**
684 **bilayer.**

685 TIRF imaging shows Alexa Fluor 647-IgG (black) in the supported lipid bilayer as a
686 macrophage engages with an IgG and CD47-bound target. Frames were acquired every
687 20 sec and time is indicated in the top left. Scale bar denotes 5 μm .

688

689 **Movie S3: An Mn-treated macrophage encounters an L1210 leukemia cell**

690 A macrophage infected with GFP- CAAX encounters an L1210 leukemia cell labeled
691 with H2B-mCherry. In the presence of 100 μM Mn^{2+} the macrophage is able to engulf
692 the cancer cell. Images were acquired every 5 min for 140 min. The field of view is 53
693 μm by 53 μm .

694

695 **References**

- 696 Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N.L., Ghosh, N., Kline, J.,
697 Roschewski, M., LaCasce, A., Collins, G.P., et al. (2018). CD47 Blockade by Hu5F9-G4
698 and Rituximab in Non-Hodgkin's Lymphoma. *N. Engl. J. Med.* 379, 1711–1721.
- 699 Alenghat, F.J., Baca, Q.J., Rubin, N.T., Pao, L.I., Matozaki, T., Lowell, C.A., Golan,
700 D.E., Neel, B.G., and Swanson, K.D. (2012). Macrophages require Skap2 and Sirpa for
701 integrin-stimulated cytoskeletal rearrangement. *J. Cell Sci.* 125, 5535–5545.
- 702 Barclay, A.N., and Brown, M.H. (2006). The SIRP family of receptors and immune
703 regulation. *Nat. Rev. Immunol.* 6, 457–464.
- 704 Birge, R.B., Boeltz, S., Kumar, S., Carlson, J., Wanderley, J., Calianese, D., Barcinski,
705 M., Brekken, R.A., Huang, X., Hutchins, J.T., et al. (2016). Phosphatidylserine is a
706 global immunosuppressive signal in efferocytosis, infectious disease, and cancer. *Cell*
707 *Death Differ.* 23, 962–978.
- 708 Campbell, H., Heidema, C., Pilarczyk, D.G., and DeMali, K.A. (2018). SHP-2 is
709 activated in response to force on E-cadherin and dephosphorylates vinculin Y822. *J.*
710 *Cell Sci.* 131, jcs216648.
- 711 Caron, E., Self, A.J., and Hall, A. (2000). The GTPase Rap1 controls functional
712 activation of macrophage integrin alphaMbeta2 by LPS and other inflammatory
713 mediators. *Curr. Biol.* 10, 974–978.
- 714 Chang, V.T., Fernandes, R.A., Ganzinger, K.A., Lee, S.F., Siebold, C., McColl, J.,
715 Jönsson, P., Palayret, M., Harlos, K., Coles, C.H., et al. (2016). Initiation of T cell
716 signaling by CD45 segregation at “close contacts”. *Nat. Immunol.* 17, 574–582.
- 717 Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M.,
718 Cha, A.C., Chan, C.K., Tan, B.T., et al. (2010a). Anti-CD47 Antibody Synergizes with
719 Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. *Cell* 142,
720 699–713.
- 721 Chao, M.P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A.A., Gentles, A.J.,
722 Volkmer, J., Weiskopf, K., Willingham, S.B., Raveh, T., Park, C.Y., et al. (2010b).
723 Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is
724 Counterbalanced by CD47. *Sci. Transl. Med.* 2, 63ra94-63ra94.
- 725 Chao, M.P., Weissman, I.L., and Majeti, R. (2012). The CD47-SIRP α pathway in cancer

726 immune evasion and potential therapeutic implications. *Curr. Opin. Immunol.* *24*, 225–
727 232.

728 Chen, J., Zhong, M.-C., Guo, H., Davidson, D., Mishel, S., Lu, Y., Rhee, I., Pérez-
729 Quintero, L.-A., Zhang, S., Cruz-Munoz, M.-E., et al. (2017). SLAMF7 is critical for
730 phagocytosis of haematopoietic tumour cells via Mac-1 integrin. *Nature* *544*, 493–497.

731 Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A.,
732 Cons, L., Calloud, S., Majocchi, S., Nelson, R., et al. (2017). Selective Blockade of the
733 Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific
734 Antibodies. *Mol. Ther.* *25*, 523–533.

735 Dransfield, I., Cabanas, C., Craig, A., and Hogg, N. (1992). Divalent Cation Regulation
736 of the Function of the Leukocyte Integrin LFA1.

737 Dupuy, A.G., and Caron, E. (2008). Integrin-dependent phagocytosis: spreading from
738 microadhesion to new concepts. *J. Cell Sci.* *121*, 1773–1783.

739 Edelstein, A., Amodaj, N., Hoover, K., Vale, R., and Stuurman, N. (2010). Computer
740 control of microscopes using manager. *Curr. Protoc. Mol. Biol.* *Chapter 14*, Unit14 20.

741 Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L., and Henson,
742 P.M. (1992). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes
743 triggers specific recognition and removal by macrophages. *J. Immunol.* *148*, 2207–
744 2216.

745 Freeman, S.A., and Grinstein, S. (2014). Phagocytosis: Receptors, signal integration,
746 and the cytoskeleton. *Immunol. Rev.* *262*, 193–215.

747 Freeman, S.A., Goyette, J., Furuya, W., Woods, E.C., Bertozzi, C.R., Bergmeier, W.,
748 Hinz, B., Van Der Merwe, P.A., Das, R., and Grinstein, S. (2016). Integrins Form an
749 Expanding Diffusional Barrier that Coordinates Phagocytosis. *Cell* *164*, 128–140.

750 Fujioka, Y., Matozaki, T., Noguchi, T., Iwamatsu, A., Yamao, T., Takahashi, N., Tsuda,
751 M., Takada, T., and Kasuga, M. (1996). A novel membrane glycoprotein, SHPS-1, that
752 binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to
753 mitogens and cell adhesion. *Mol. Cell. Biol.* *16*, 6887–6899.

754 Gardai, S.J., McPhillips, K.A., Frasch, S.C., Janssen, W.J., Starefeldt, A., Murphy-
755 Ullrich, J.E., Bratton, D.L., Oldenborg, P.-A.A., Michalak, M., and Henson, P.M. (2005).
756 Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-

757 activation of LRP on the phagocyte. *Cell* 123, 321–334.

758 Gardner, B., Anstee, D.J., Mawby, W.J., Tanner, M.J., and von dem Borne, A.E. (1991).

759 The abundance and organization of polypeptides associated with antigens of the Rh

760 blood group system. *Transfus. Med.* 1, 77–85.

761 Geiger, B., Spatz, J.P., and Bershadsky, A.D. (2009). Environmental sensing through

762 focal adhesions. *Nat. Rev. Mol. Cell Biol.* 10, 21–33.

763 Gholamin, S., Mitra, S.S., Feroze, A.H., Liu, J., Kahn, S.A., Zhang, M., Esparza, R.,

764 Richard, C., Ramaswamy, V., Remke, M., et al. (2017). Disrupting the CD47-SIRP α

765 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for

766 malignant pediatric brain tumors. *Sci. Transl. Med.* 9, eaaf2968.

767 Goodridge, H.S., Reyes, C.N., Becker, C.A., Katsumoto, T.R., Ma, J., Wolf, A.J., Bose,

768 N., Chan, A.S.H., Magee, A.S., Danielson, M.E., et al. (2011). Activation of the innate

769 immune receptor Dectin-1 upon formation of a ‘phagocytic synapse.’ *Nature* 472, 471–

770 475.

771 Hatherley, D., Graham, S.C., Turner, J., Harlos, K., Stuart, D.I., and Barclay, A.N.

772 (2008). Paired Receptor Specificity Explained by Structures of Signal Regulatory

773 Proteins Alone and Complexed with CD47. *Mol. Cell* 31, 266–277.

774 Hui, E., and Vale, R.D. (2014). In vitro membrane reconstitution of the T-cell receptor

775 proximal signaling network. *Nat. Struct. Mol. Biol.* 21, 133–142.

776 Inagaki, K., Yamao, T., Noguchi, T., Matozaki, T., Fukunaga, K., Takada, T., Hosooka,

777 T., Akira, S., and Kasuga, M. (2000). SHPS-1 regulates integrin-mediated cytoskeletal

778 reorganization and cell motility. *EMBO J.* 19, 6721–6731.

779 Jaiswal, S., Jamieson, C.H.M., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver,

780 D., van Rooijen, N., and Weissman, I.L. (2009). CD47 Is Upregulated on Circulating

781 Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. *Cell* 138, 271–

782 285.

783 James, J.R., and Vale, R.D. (2012). Biophysical mechanism of T-cell receptor triggering

784 in a reconstituted system. *Nature* 487, 64–69.

785 Jiang, P., Lagenaur, C.F., and Narayanan, V. (1999). Integrin-associated protein is a

786 ligand for the P84 neural adhesion molecule. *J. Biol. Chem.* 274, 559–562.

787 Jones, S.L., Knaus, U.G., Bokoch, G.M., and Brown, E.J. (1998). Two signaling

788 mechanisms for activation of alphaM beta2 avidity in polymorphonuclear neutrophils. *J.*
789 *Biol. Chem.* 273, 10556–10566.

790 Lin, J., Kurilova, S., Scott, B.L., Bosworth, E., Iverson, B.E., Bailey, E.M., and Hoppe,
791 A.D. (2016). TIRF imaging of Fc gamma receptor microclusters dynamics and signaling
792 on macrophages during frustrated phagocytosis. *BMC Immunol.* 17, 5.

793 Liu, D.Q., Li, L.M., Guo, Y.L., Bai, R., Wang, C., Bian, Z., Zhang, C.Y., and Zen, K.
794 (2008). Signal regulatory protein α negatively regulates β 2 integrin-mediated monocyte
795 adhesion, transendothelial migration and phagocytosis. *PLoS One* 3.

796 Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., Xu, H., Peng, H., Fu, Y.-X.,
797 and Xu, M.M. (2015). CD47 blockade triggers T cell-mediated destruction of
798 immunogenic tumors. *Nat. Med.* 21, 1209–1215.

799 Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D., van
800 Rooijen, N., and Weissman, I.L. (2009). CD47 Is an Adverse Prognostic Factor and
801 Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. *Cell* 138,
802 286–299.

803 Matlung, H.L., Babes, L., Zhao, X.W., van Houdt, M., Treffers, L.W., van Rees, D.J.,
804 Franke, K., Schornagel, K., Verkuijlen, P., Janssen, H., et al. (2018). Neutrophils Kill
805 Antibody-Opsonized Cancer Cells by Trogoptosis. *Cell Rep.* 23, 3946-3959.e6.

806 Michaels, A.D., Newhook, T.E., Adair, S.J., Morioka, S., Goudreau, B.J., Nagdas, S.,
807 Mullen, M.G., Persily, J.B., Bullock, T.N.J., Slingluffjr, C.L., et al. (2017). Cancer
808 Therapy: Preclinical CD47 Blockade as an Adjuvant Immunotherapy for Resectable
809 Pancreatic Cancer.

810 Motegi, S. -i., Okazawa, H., Ohnishi, H., Sato, R., Kaneko, Y., Kobayashi, H.,
811 Tomizawa, K., Ito, T., Honma, N., Bühring, H., et al. (2003). Role of the CD47-SHPS-1
812 system in regulation of cell migration. *EMBO J.* 22, 2634–2644.

813 Mouro-Chanteloup, I., Delaunay, J., Gane, P., Nicolas, V., Johansen, M., Brown, E.J.,
814 Peters, L.L., Van Kim, C. Le, Cartron, J.P., and Colin, Y. (2003). Evidence that the red
815 cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. *Blood*
816 101, 338–344.

817 Noguchi, T., Matozaki, T., Fujioka, Y., Yamao, T., Tsuda, M., Takada, T., and Kasuga,
818 M. (1996). Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-

819 tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells. *J.*
820 *Biol. Chem.* *271*, 27652–27658.

821 O'Donoghue, G.P., Pielak, R.M., Smoligovets, A.A., Lin, J.J., and Groves, J.T. (2013).
822 Direct single molecule measurement of TCR triggering by agonist pMHC in living
823 primary T cells. *Elife* *2*.

824 Okazawa, H., Motegi, S. -i., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y.,
825 Oldenborg, P.-A., Ishikawa, O., and Matozaki, T. (2005). Negative Regulation of
826 Phagocytosis in Macrophages by the CD47-SHPS-1 System. *J. Immunol.* *174*, 2004–
827 2011.

828 Oldenborg, P.-A., Gresham, H.D., and Lindberg, F.P. (2001). Cd47-Signal Regulatory
829 Protein α (Sirp α) Regulates Fc γ and Complement Receptor–Mediated Phagocytosis. *J.*
830 *Exp. Med.* *193*, 855–862.

831 Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gresham, H.D., and
832 Lindberg, F.P. (2000). Role of CD47 as a marker of self on red blood cells. *Science* *288*,
833 2051–2054.

834 Panni, R.Z., Herndon, J.M., Zuo, C., Hegde, S., Hogg, G.D., Knolhoff, B.L., Breden,
835 M.A., Li, X., Krisnawan, V.E., Khan, S.Q., et al. (2019). Agonism of CD11b reprograms
836 innate immunity to sensitize pancreatic cancer to immunotherapies. *Sci. Transl. Med.*
837 *11*, eaau9240.

838 Poon, I.K.H., Lucas, C.D., Rossi, A.G., and Ravichandran, K.S. (2014). Apoptotic cell
839 clearance: basic biology and therapeutic potential. *Nat. Rev. Immunol.* *14*, 166–180.

840 Schmid, E.M., Bakalar, M.H., Choudhuri, K., Weichsel, J., Ann, H.S., Geissler, P.L.,
841 Dustin, M.L., and Fletcher, D.A. (2016). Size-dependent protein segregation at
842 membrane interfaces. *Nat. Phys.* *12*, 704–711.

843 Schmid, M.C., Khan, S.Q., Kaneda, M.M., Pathria, P., Shepard, R., Louis, T.L., Anand,
844 S., Woo, G., Leem, C., Faridi, M.H., et al. (2018). Integrin CD11b activation drives anti-
845 tumor innate immunity. *Nat. Commun.* *9*, 5379.

846 Seiffert, M., Cant, C., Chen, Z., Rappold, I., Brugger, W., Kanz, L., Brown, E.J., Ullrich,
847 A., and Bühring, H.J. (1999). Human signal-regulatory protein is expressed on normal,
848 but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving
849 its counterreceptor CD47. *Blood* *94*, 3633–3643.

850 Spencer, D.M., Wandless, T.J., Schreiber, S.L., and Crabtree, G.R. (1993). Controlling
851 signal transduction with synthetic ligands. *Science* 262, 1019–1024.

852 Springer, T.A., and Dustin, M.L. (2011). Integrin inside-out signaling and the
853 immunological synapse. *Curr. Opin. Cell Biol.* 24, 107–115.

854 Subramanian, S., Parthasarathy, R., Sen, S., Boder, E.T., and Discher, D.E. (2006).
855 Species-and cell type-specific interactions between CD47 and human SIRP α . *Blood*
856 107, 2548–2556.

857 Tamada, M., Sheetz, M.P., and Sawada, Y. (2004). Activation of a Signaling Cascade
858 by Cytoskeleton Stretch. *Dev. Cell* 7, 709–718.

859 Tsai, R.K., and Discher, D.E. (2008). Inhibition of “self” engulfment through deactivation
860 of myosin-II at the phagocytic synapse between human cells. *J. Cell Biol.* 180, 989–
861 1003.

862 Tseng, D., Volkmer, J.-P.J.-P., Willingham, S.B., Contreras-Trujillo, H., Fathman, J.W.,
863 Fernhoff, N.B., Seita, J., Inlay, M.A., Weiskopf, K., Miyanishi, M., et al. (2013). Anti-
864 CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective
865 antitumor T-cell response. *Proc. Natl. Acad. Sci.* 110, 11103–11108.

866 Utsugi, T., Schroit, A.J., Connor, J., Bucana, C.D., and Fidler, I.J. (1991). Elevated
867 expression of phosphatidylserine in the outer membrane leaflet of human tumor cells
868 and recognition by activated human blood monocytes. *Cancer Res.* 51, 3062–3066.

869 Veillette, A., Thibaudeau, E., and Latour, S. (1998). High expression of inhibitory
870 receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in
871 macrophages. *J. Biol. Chem.* 273, 22719–22728.

872 Weischenfeldt, J., and Porse, B. (2008). Bone Marrow-Derived Macrophages (BMM):
873 Isolation and Applications. *CSH Protoc.* 2008, pdb.prot5080.

874 Willingham, S.B., Volkmer, J.-P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S.,
875 Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., et al. (2012). The CD47-signal
876 regulatory protein alpha (SIRP α) interaction is a therapeutic target for human solid
877 tumors. *Proc. Natl. Acad. Sci.* 109, 6662–6667.

878 Wong, H.S., Jaumouillé, V., Freeman, S.A., Doodnauth, S.A., Schlam, D., Canton, J.,
879 Mukovozov, I.M., Saric, A., Grinstein, S., and Robinson, L.A. (2016). Chemokine
880 Signaling Enhances CD36 Responsiveness toward Oxidized Low-Density Lipoproteins

881 and Accelerates Foam Cell Formation. *Cell Rep.* *14*, 2859–2871.

882 Wu, J., Wu, H., An, J., Ballantyne, C.M., and Cyster, J.G. (2018). Critical role of integrin
883 CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive
884 immunity. *Proc. Natl. Acad. Sci.* 201805542.

885 Yi, T., Li, J., Chen, H., Hu, Y., Lowell, C.A., and Cyster Correspondence, J.G. (2015).
886 Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger
887 Adaptive Immune Responses. *Immunity* *43*, 764–775.

888 Yu, D.H., Qu, C.K., Henegariu, O., Lu, X., and Feng, G.S. (1998). Protein-tyrosine
889 phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. *J. Biol.*
890 *Chem.* *273*, 21125–21131.

891

892

Figure 1: CD47-SIRPA suppresses IgG and PS dependent engulfment




Figure 2: Forcing SIRPA into the macrophage-target synapse suppresses engulfment




Figure 3: CD47 prevents integrin activation




Figure 4: Bypassing integrin activation eliminates the effect of CD47.

